Abstract
Background
In recent years, medical controversy, has surrounded the prescribing of hormone replacement therapy (HRT).
Aim
This study aimed to establish whether prescribing of HRT in Northern Ireland has changed and what the current prescribing patterns are.
Method
A structured questionnaire was sent by post to all medical staff in Obstetrics and Gynaecology in Northern Ireland. A stamped addressed envelope was included.
Results
Overall 54% of respondents indicated that they had changed their prescribing practice on HRT in the past year. The primary indication for prescribing HRT was vasomotor symptoms (93%). Fifty-six per cent of doctors recommended 1–5 years as duration of use. Oral preparations were those most commonly prescribed (57%). The dose and type chosen were the same whether prescribing had changed or not.
Conclusions
More than half of all doctors who responded had changed their prescribing practices on HRT, yet some respondents still preferred more traditional prescribing.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Million Women Study Collaborators. Breast cancer and hormonereplacement therapy in the Million Women Study.Lancet 2003; 362: 419–427.
Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of oestrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomised controlled trial.JAMA 2002: 288: 321–33.
Further confusion in postmenopausal health: Committee on Safety of Medicines Message 3rd December 2003.
Cauley JA, Zmuda JM, Ensrud KE, Bauer DC, Ettinger B. Timing of oestrogen replacement therapy for optimal osteoporosis prevention.J Clin Endocrinol Metab 2001; 86:5700–5.
Cauley JA, Robbins J, Chen Z, et al Women’s Health Initiative Investigators. Effects of oestrogen plus progestin on risk of fracture and bone mineral density: the Woman’s Health Initiative randomised trial.JAMA 2003; 290:1729–38.
Marcus R, Wong M, Heath H, Stock JLAntiresorptive treatment of postmenopausal osteoporosis: comparisons of study designs and outcomes in large clinical trials with fracture as an endpoint.Endocr Rev 2002; 23:16–37.
Chavassieux PM, Arlot ME, Reda C et al Histomorphometric assessment of the long-term effects of alendronate on bone quality and remodelling in patients with osteoporosisJ Clin Invest 1997; 100: 1475–80.
Ettinger B, Black DM, Mitlak BH, et al Reduction in vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomised clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.JAMA 1999; 282: 637–45.
Royal College of Physicians. Osteoporosis: clinical guidelines for prevention and treatment. Update on pharmacological interventions and an algorithm for management. London, Royal College of Physicians 2000.
Stevenson J. Hormone Replacement Therapy and Breast Cancer: a Response to the Million Women Study from Women’s Health Concern. Press Release from the British Menopause Society; August 2003.
Marsden J, Sacks N. The national randomised trial of hormone replacement therapy in women with a history of early stage breast cancer: an updateJ B Menopause Soc 2002; 8:129.
La Vecchia C, Brinton LA, McTiernan A. Cancer risk in menopausal women.Best Pract Res Clin Obstet Cynaecol 2002; 16: 293–307.
Lundstrom E, Christow A, Kersemaekers W et al Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density.Am J Obstet Gynaecol 2002; 186:717–722.
Managing the Menopause. British Menopause Society Council Consensus Statement on Hormone Replacement Therapy. January 2004.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Conlon, O., McKinney, K. HRT: Have we changed?. Ir J Med Sci 175, 58–61 (2006). https://doi.org/10.1007/BF03167969
Issue Date:
DOI: https://doi.org/10.1007/BF03167969